Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma.

IgE plays an important role in allergic asthma. We hypothesized that reducing IgE in the airway mucosa would reduce airway inflammation. Forty-five patients with mild to moderate persistent asthma with sputum eosinophilia of 2% or more were treated with humanized monoclonal antibody against IgE (omalizumab) (n = 22) or placebo (n = 23) for 16 weeks. Outcomes included inflammatory cells in induced sputum and bronchial biopsies, and methacholine responsiveness. Treatment with omalizumab resulted in marked reduction of serum IgE and a reduction of IgE+ cells in the airway mucosa. The mean percentage sputum eosinophil count decreased significantly (p < 0.001) from 6.6 to 1.7% in the omalizumab group, a reduction significantly (p = 0.05) greater than with placebo (8.5 to 7.0%). This was associated with a significant reduction in tissue eosinophils; cells positive for the high-affinity Fc receptor for IgE; CD3+, CD4+, and CD8+ T lymphocytes; B lymphocytes; and cells staining for interleukin-4, but not with improvement in airway hyperresponsiveness to methacholine. This study shows antiinflammatory effects of omalizumab treatment and provides clues for mechanisms whereby omalizumab reduces asthma exacerbations and other asthma outcomes in more severe asthma. The lack of effect of omalizumab on methacholine responsiveness suggests that IgE or eosinophils may not be causally linked to airway hyperresponsiveness to methacholine in mild to moderate asthma.

[1]  R. Geha,et al.  Human recombinant interleukin 4 induces Fc epsilon R2/CD23 on normal human monocytes , 1988, The Journal of experimental medicine.

[2]  M. Kehry,et al.  Low-affinity IgE receptor (CD23) function on mouse B cells: role in IgE-dependent antigen focusing. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[3]  A. Wardlaw,et al.  The activated eosinophil in allergy and asthma. , 1989, Progress in clinical and biological research.

[4]  J. Ring,et al.  Induction of Fc epsilon R2/CD23 on human epidermal Langerhans cells by human recombinant interleukin 4 and gamma interferon , 1989, The Journal of experimental medicine.

[5]  F. Martinez,et al.  Association of asthma with serum IgE levels and skin-test reactivity to allergens. , 1989, The New England journal of medicine.

[6]  R. Djukanović,et al.  Mucosal inflammation in asthma. , 1990, The American review of respiratory disease.

[7]  M. Sears,et al.  Relation between airway responsiveness and serum IgE in children with asthma and in apparently normal children. , 1991, The New England journal of medicine.

[8]  F. Luscinskas,et al.  IL-4 induces adherence of human eosinophils and basophils but not neutrophils to endothelium. Association with expression of VCAM-1. , 1992, Journal of immunology.

[9]  P. Howarth,et al.  Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. , 1992, The American review of respiratory disease.

[10]  P. Howarth,et al.  Immunolocalization of cytokines in the nasal mucosa of normal and perennial rhinitic subjects. The mast cell as a source of IL-4, IL-5, and IL-6 in human allergic mucosal inflammation. , 1993, Journal of immunology.

[11]  J. Bos,et al.  Serum-IgE-facilitated allergen presentation in atopic disease. , 1993, Journal of immunology.

[12]  H. Boushey,et al.  Analysis of induced sputum to examine the effects of prednisone on airway inflammation in asthmatic subjects. , 1994, The Journal of allergy and clinical immunology.

[13]  P. Howarth,et al.  Interleukin-4, -5, and -6 and tumor necrosis factor-alpha in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. , 1994, American journal of respiratory cell and molecular biology.

[14]  R. Martin,et al.  Dysregulation of interleukin 4, interleukin 5, and interferon gamma gene expression in steroid-resistant asthma , 1995, The Journal of experimental medicine.

[15]  L. Presta,et al.  Inhibition of allergic reactions with antibodies to IgE. , 1995, International archives of allergy and immunology.

[16]  S. Holgate,et al.  Expression of the high affinity receptor for immunoglobulin E (IgE) by dendritic cells in normals and asthmatics. , 1995, Advances in experimental medicine and biology.

[17]  S. Durham,et al.  High-affinity IgE receptor (FcepsilonRI)-bearing cells in bronchial biopsies from atopic and nonatopic asthma. , 1996, American journal of respiratory and critical care medicine.

[18]  P. Howarth,et al.  Effect of natural allergen exposure during the grass pollen season on airways inflammatory cells and asthma symptoms. , 1996, Thorax.

[19]  C. Bertrand,et al.  Central role of immunoglobulin (Ig) E in the induction of lung eosinophil infiltration and T helper 2 cell cytokine production: inhibition by a non-anaphylactogenic anti-IgE antibody , 1996, The Journal of experimental medicine.

[20]  P. Howarth,et al.  The effect of treatment with oral corticosteroids on asthma symptoms and airway inflammation. , 1997, American journal of respiratory and critical care medicine.

[21]  H. Boushey,et al.  The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. , 1997, American journal of respiratory and critical care medicine.

[22]  F. Levi-Schaffer,et al.  The human mast cell. , 1997, The Journal of allergy and clinical immunology.

[23]  Third Expert Panel on theDiagnosis,et al.  Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma , 1997 .

[24]  L. Boulet,et al.  Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. , 1997, American journal of respiratory and critical care medicine.

[25]  A. Togias,et al.  Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. , 1997, Journal of immunology.

[26]  K. Rabe.  Mechanisms of immune sensitization of human bronchus. , 1998, American journal of respiratory and critical care medicine.

[27]  R. Djukanović,et al.  Safety of biopsies and bronchoalveolar lavage. , 1998, The European respiratory journal. Supplement.

[28]  A. Zwinderman,et al.  Effect of inhaled steroids on airway hyperresponsiveness, sputum eosinophils, and exhaled nitric oxide levels in patients with asthma , 1999, Thorax.

[29]  K. Chung,et al.  Effect of inhaled budesonide on lung function and airway inflammation. Assessment by various inflammatory markers in mild asthma. , 1999, American journal of respiratory and critical care medicine.

[30]  D S Pearlman,et al.  Pathophysiology of the inflammatory response. , 1999, The Journal of allergy and clinical immunology.

[31]  L. Borish,et al.  Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. , 1999, American journal of respiratory and critical care medicine.

[32]  Salvi Ss,et al.  Treatment of allergic asthma with monoclonal anti-IgE antibody. , 1999 .

[33]  R. Bush,et al.  Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. , 1999, The New England journal of medicine.

[34]  K. Chung,et al.  Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsìveness, and the late asthmatic response , 2000, The Lancet.

[35]  R. Djukanović,et al.  The relationship between airways inflammation and asthma severity. , 2000, American journal of respiratory and critical care medicine.

[36]  R. Townley,et al.  The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. , 2001, The European respiratory journal.

[37]  H. Milgrom,et al.  Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). , 2001, Pediatrics.

[38]  T. Wrin,et al.  Anti-IgE efficacy in murine asthma models is dependent on the method of allergen sensitization. , 2001, The Journal of allergy and clinical immunology.

[39]  T. Platts-Mills.  The role of immunoglobulin E in allergy and asthma. , 2001, American journal of respiratory and critical care medicine.

[40]  P. O'Byrne,et al.  The trials and tribulations of IL-5, eosinophils, and allergic asthma. , 2001, The Journal of allergy and clinical immunology.

[41]  M. Hlastala,et al.  Perfluorocarbon enhanced gas exchange: the easy way. , 2001, American journal of respiratory and critical care medicine.

[42]  W. Busse,et al.  Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. , 2001, The Journal of allergy and clinical immunology.

[43]  W. Busse,et al.  Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. , 2001, The Journal of allergy and clinical immunology.

[44]  I. Pavord,et al.  Mast-cell infiltration of airway smooth muscle in asthma. , 2002, The New England journal of medicine.

[45]  T. Sandström,et al.  The effect of omalizumab on nasal allergic inflammation. , 2002, The Journal of allergy and clinical immunology.

[46]  A. James,et al.  Distribution and degranulation of airway mast cells in normal and asthmatic subjects , 2002, European Respiratory Journal.

[47]  I. Pavord,et al.  Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial , 2002, The Lancet.

[48]  Charles A. Johnson,et al.  Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma , 2003, Current medical research and opinion.

[49]  D. Postma,et al.  Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. , 2003, American journal of respiratory and critical care medicine.

[50]  S. Phipps,et al.  Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. , 2003, The Journal of clinical investigation.

[51]  O. Noga,et al.  Immunological and Clinical Changes in Allergic Asthmatics following Treatment with Omalizumab , 2003, International Archives of Allergy and Immunology.